Author

T. Hatschek

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A.-L. Borresen-Dale· 1 shared I. Hedenfalk· 1 shared J. Ankill· 1 shared J. Tost· 1 shared L. Silwal-Pandit· 1 shared M. H. Haugen· 1 shared O. Engebraaten· 1 shared T. Fleischer· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A.-L. Borresen-Dale

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

An integrated 'omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumab

T. Fleischer, M. H. Haugen, J. Ankill, L. Silwal-Pandit, A.-L. Borresen-Dale, I. Hedenfalk, T. Hatschek, J. Tost, O. Engebraaten, V. N. Kristensen

This study uses an integrated omics approach to show that DNA methylation at enhancer CpGs can predict response to neoadjuvant chemotherapy and bevacizumab in ER-positive patients.

bioRxiv · Jul 6, 2022 · PreprintCancer Biology